Kodiak Sciences Inc.
KOD
Classificação em ações
#3149
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Preço da ação
$91.35
Última sincronização: 2026-10-19
Valor de mercado
$5.74B
Variação (1 dia)
6.53%
Variação (1 ano)
416.10%
País
US
Negociar Kodiak Sciences Inc. (KOD)
Categoria
Healthcare
Lucros da Kodiak Sciences Inc. (KOD)
Lucros em Jun 2026 TTM: $-241.99M
De acordo com os últimos relatórios financeiros da Kodiak Sciences Inc., os ganhos atuais da empresa são de $-241.99M. Em 2023, a empresa teve ganhos de $-260.49M, um aumento em relação a aos ganhos de 2022, que foram de $-333.82M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Kodiak Sciences Inc. de 2016 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $-241.99M | 37.34% |
| 2024 | $-176.21M | -32.36% |
| 2023 | $-260.49M | -21.97% |
| 2022 | $-333.82M | 25.03% |
| 2021 | $-266.99M | 100.60% |
| 2020 | $-133.10M | 181.00% |
| 2019 | $-47.37M | 14.29% |
| 2018 | $-41.44M | 48.35% |
| 2017 | $-27.94M | 63.06% |
| 2016 | $-17.13M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | -2,279.76% |
US
|
|
| $-3.09B | 1,175.65% |
US
|
|
| $-4.02B | 1,559.63% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -906.07% |
NL
|
